(Q34412708)

2 August 2017

1 reference

title

Taking aim at HDL-C. Raising levels to reduce cardiovascular risk (English)

1 reference

2 August 2017

Mark E McGovern

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

2 August 2017

published in

Postgraduate Medicine

1 reference

2 August 2017

volume

117

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

29-30, 33-5, 39 passim

1 reference

The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

High-density lipoprotein subfractions and risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Extended-release niacin/lovastatin: the first combination product for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Effectiveness of statin therapy in adults with coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Pharmacotherapy for dyslipidaemia – current therapies and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Optimal therapy of low levels of high density lipoprotein-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Evidence-based guidelines for cardiovascular disease prevention in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Extended-release niacin for modifying the lipoprotein profile

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2005.04.1610

21 January 2018

Identifiers

DOI

10.3810/PGM.2005.04.1610

1 reference

2 August 2017

1 reference